Effect of astaxanthin supplementation on oxidative stress in adult women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials
Main Article Content
Abstract
Background
Polycystic ovary syndrome (PCOS) can cause significant morbidity through fertility disorders and most often found in the productive age. Recent research suggests that oxidative stress plays an important role in the pathogenesis of PCOS. Astaxanthin (AST) has broad protective effects, particularly in the regulation of antioxidant and anti-inflammatory activity. The objective of this systematic review and meta-analysis was to evaluate the efficacy of AST supplementation on PCOS management.
Methods
A systematic literature search was conducted in PubMed, Scopus, Science Direct, and Cochrane Library from January 2020 to March 2025. Randomized controlled trials (RCTs) assessing astaxanthin supplementation in adult women with PCOS were included. Outcomes of interest were malondialdehyde (MDA), superoxide dismutase (SOD), and total antioxidant capacity (TAC). Data were analyzed using Review Manager (RevMan) version 5.4.1. Pooled effects were calculated as mean differences (MDs) with 95% confidence intervals (CIs).
Results
Four RCTs involving 194 participants were included. Astaxanthin supplementation significantly reduced MDA levels (MD −0.670; 95% CI −1.070 to −0.270; p = 0.001; I² = 93%) and significantly increased TAC levels (MD 0.030; 95% CI 0.000 to 0.060; p = 0.030; I² = 76%). No significant effect was observed on SOD levels (MD 0.025; 95% CI −0.850 to 1.350; p = 0.660; I² = 57%). The overall risk of bias across included studies was low.
Conclusion
This systematic review shows that AST supplementation significantly reduced lipid peroxidation in women with PCOS. These findings suggest that AST may serve as potential adjuvant antioxidant therapy in PCOS management.
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
How to Cite
References
1. Sengupta P, Dutta S, Hassan MF. Polycystic ovary syndrome (PCOS) and oxidative stress. J Integr Sci Technol 2024;12:752. DOI:10.62110/sciencein.jist.2024.v12.752
2. Azziz R, Carmina E, Chen Z. Polycystic ovary syndrome. Nat Rev Dis Primers 2016;2:1-18. https://doi.org/10.1038/nrdp.2016.57.
3. de Loos AD, Jiskoot G, Beerthuizen A, Busschbach J, Laven J. Metabolic health during a randomized controlled lifestyle intervention in women with PCOS. Eur J Endocrinol 2021;186:53-64.https://doi.org/10.1530/eje-21-0669.
4. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril 2016;106:6-15. https://doi.org/10.1016/j.fertnstert.2016.05.003.
5. Salari N, Nankali A, Ghanbari A, et al. Global prevalence of polycystic ovary syndrome in women worldwide: a comprehensive systematic review and meta-analysis. Arch Gynecol Obstet 2024;310:1303-14.https://doi.org/10.1007/s00404-024-07607-x.
6. Zia A, Farkhondeh T, Pourbagher-Shahri AM, Samarghandian S. The role of curcumin in aging and senescence: Molecular mechanisms. Biomed Pharmacother 2021;134:111119.https://doi.org/10.1016/j.biopha.2020.111119.
7. Kaur H, Pandey M, Agrawal A, Nigam A, Verma SK, Sharma DP. Nutritional status and dietary consumption trends in women with PCOS: association with obesity. Health Promot Prac 2025;11:12.https://doi.org/10.1177/00368504251392606.
8. Joham AE, Rees DA, Shinkai K, Forslund M, Tay CT, Teede HJ. Polycystic ovary syndrome: origins and implications: epidemiological aspects of polycystic ovary syndrome. Reproduction 2025;170.https://doi.org/10.1530/REP-25-0121
9. Li W, Liu C, Yang Q, Zhou Y, Liu M, Shan H. Oxidative stress and antioxidant imbalance in ovulation disorder in patients with polycystic ovary syndrome. Front Nutr 2022;9:1018674.https://doi.org/10.3389/fnut.2022.1018674.
10. Li Q, Li L, Zhang Y, Gao H, Zhao Y, Yu X. Chemical inducers regulate ROS signalling to stimulate astaxanthin production in Haematococcus pluvialis under environmental stresses: a review. Trends Food Sci Technol 2023;136:181-93.https://doi.org/10.1016/j.tifs.2023.04.014.
11. Carmina E, Guastella E, Longo RA. Advances in the diagnosis and treatment of PCOS. Curr Pharm Des 2016;22:5508-14. https://doi.org/10.2174/1381612822666160719105808.
12. Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What's new? Adv Clin Exp Med 2017;26.https://doi.org/10.17219/acem/59380.
13. Dapas M, Dunaif A. Deconstructing a syndrome: genomic insights into PCOS causal mechanisms and classification. Endocr Rev. 2022;43:927-65. https://doi.org/10.1210/endrev/bnac001.
14. Crespo RP, Bachega TA, Mendonça BB, Gomes LG. An update of genetic basis of PCOS pathogenesis. Arch Endocrinol Metab 2018;62:352-61. https://doi.org/10.20945/2359-3997000000049.
15. Pratiwi D, Sidartha M, Wiyarta E, et al. Comparison of the risk of obesity in the FTO rs9939609 genotype in a multiethnic group in Asia systematic review and meta-analysis. Front Med 2025;12:1522318. https://doi.org/10.3389/fmed.2025.1522318.
16. Awonuga AO, Camp OG, Abu-Soud HM. A review of nitric oxide and oxidative stress in typical ovulatory women and in the pathogenesis of ovulatory dysfunction in PCOS. Reprod Biol Endocrinol 2023;21:111.https://doi.org/10.1186/s12958-023-01159-6.
17. Gnanadass SA, Prabhu YD, Gopalakrishnan AV. Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update. Arch Gynecol Obstet 2021;303:631-43.https://doi.org/10.1007/s00404-020-05951-2.
18. Chen W, Pang Y. Metabolic Syndrome and PCOS: Pathogenesis and the role of metabolites. Metabolites 2021;11: 869.https://doi.org/10.3390/metabo11120869.
19. Nair A, Ahirwar A, Singh S, et al. Astaxanthin as a king of ketocarotenoids: structure, synthesis, accumulation, bioavailability and antioxidant properties. Marine Drugs 2023;21:176.https://doi.org/10.3390/md21030176.
20. Bjørklund G, Gasmi A, Lenchyk L, et al. The role of astaxanthin as a nutraceutical in health and age-related conditions. Molecules 2022;27: 7167.https://doi.org/10.3390/molecules27217167.
21. Jabarpour M, Aleyasin A, Nashtaei MS, Lotfi S, Amidi F. Astaxanthin treatment ameliorates ER stress in polycystic ovary syndrome patients: a randomized clinical trial. Sci Rep 2023;13:3376.https://doi.org/10.1111/jcmm.18464.
22. Fakhri S, Abbaszadeh F, Dargahi L, Jorjani M. Astaxanthin: a mechanistic review on its biological activities and health benefits. Pharmacol Res 2018;136:1-20.https://doi.org/10.1016/j.phrs.2018.08.012.
23. Uçkan K, Demir H, Turan K, Sarıkaya E, Demir C. Role of oxidative stress in obese and nonobese PCOS patients. Int J Clin Pract 2022;2022:4579831.https://doi.org/10.1155/2022/4579831.
24. Brotosudarmo THP, Limantara L, Setiyono E, Heriyanto. Structures of astaxanthin and their consequences for therapeutic application. Int J Food Sci 2020;2020:2156582. https://doi.org/10.1155/2020/2156582.
25. Davinelli S, Nielsen ME, Scapagnini G. Astaxanthin in skin health, repair, and disease: a comprehensive review. Nutrients 2018;10:522.https://doi.org/10.3390/nu10040522.
26. Nishida Y, Nawaz A, Hecht K, Tobe K. Astaxanthin as a novel mitochondrial regulator: a new aspect of carotenoids, beyond antioxidants. Nutrients 2021;14:107. https://doi.org/10.3390/nu14010107.
27. Kumar S, Kumar R, Diksha, Kumari A, Panwar A. Astaxanthin: A super antioxidant from microalgae and its therapeutic potential. J Basic Microbiol 2022;62:1064-82. https://doi.org/10.1002/jobm.202100391.
28. Tugwell P, Tovey D. PRISMA 2020. J Clin Epidemiol 2021;134:A5-A6. doi: 10.1016/j.jclinepi.2021.04.008.
29. Baumann N. How to use the medical subject headings (MeSH). Int J Clin Pract 2016;70:171-4. https://doi.org/10.1111/ijcp.12767
30. Amir-Behghadami M, Janati A. Population, intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emerg Med J 2020; 37:387.https://doi.org/10.1136/emermed-2020-209567.
31. Brown D. A review of the PubMed PICO tool: using evidence-based practice in health education. Health Promot Pract 2020;21:496-8. https://doi.org/10.1177/1524839919893361.
32. Crocker TF, Lam N, Jordao M, et al. Risk-of-bias assessment using Cochrane's revised tool for randomized trials (RoB 2) was useful but challenging and resource-intensive: observations from a systematic review. J Clin Epidemiol 2023;161:39-45. https://doi.org/10.1016/j.jclinepi.2023.06.015.
33. Gharaei R, Alyasin A, Mahdavinezhad F, Samadian E, Ashrafnezhad Z, Amidi F. Randomized controlled trial of astaxanthin impacts on antioxidant status and assisted reproductive technology outcomes in women with polycystic ovarian syndrome. J Assist Reprod Genet 2022;39:995-1008. https://doi.org/10.1007/s10815-022-02432-0.
34. Rostami S, Alyasin A, Saedi M, et al. Astaxanthin ameliorates inflammation, oxidative stress, and reproductive outcomes in endometriosis patients undergoing assisted reproduction: A randomized, triple-blind placebo-controlled clinical trial. Front Endocrinol (Lausanne) 2023;14:1144323. https://doi.org/10.3389/fendo.2023.1144323.
35. Shafie A, Ashraf A, Mojtaba S, et al. Astaxanthin improves assisted reproductive technology outcomes in poor ovarian responders through alleviating oxidative stress, inflammation, and apoptosis: a randomized clinical trial. Int J Clin Pract 2024;17:212. https://doi.org/10.1186/s13048-024-01537-7.
36. Donoso A, González-Durán J, Muñoz AA, González PA, Agurto-Muñoz C. Therapeutic uses of natural astaxanthin: An evidence-based review focused on human clinical trials. Pharmacol Res 2021;166:105479. https://doi.org/10.1016/j.phrs.2021.105479.
37. Si P, Zhu C. Biological and neurological activities of astaxanthin (Review). Mol Med Rep 2022;26:300.https://doi.org/10.3892/mmr.2022.12816.
38. Tambat VS, Singhania RR, Sumathi Y, et al. Astaxanthin: nature's multifunctional molecule, natural sources, health benefits, and process advancements. Crit Rev Biotechnol 2026;46:61-79. https://doi.org/10.1080/07388551.2025.2537816.
39. Rambaldi A, Paris F, Marrazzo P, Costa R, Ratti S, Alviano F. Marine-derived astaxanthin: molecular mechanisms, biomedical applications, and roles in stem cell biology. Mar Drugs 2025;23:235. doi: 10.3390/md23060235.
40. Bar-Or D, Bar-Or R, Rael LT. Oxidative stress in severe acute illness. Redox Biol 2015;4:340-5. https://doi.org/10.1016/j.redox.2015.01.006.
41. Alugoju P, Krishna Swamy VK, Anthikapalli NV, Tencomnao T. Health benefits of astaxanthin against age-related diseases of multiple organs: a comprehensive review. Crit Rev Food Sci Nutr 2023;63:10709-74. https://doi.org/10.1080/10408398.2022.2084600.
42. Abdelazim K, Ghit A, Assal D, et al. Production and therapeutic use of astaxanthin in the nanotechnology era. Pharmacol Rep 2023;75:771-90. https://doi.org/10.1007/s43440-023-00488-y.
43. Rudnicka E, Duszewska AM, Kucharski M. Oxidative stress and reproductive function: oxidative stress in polycystic ovary syndrome. Reproduction 2022;164:F145-F54. https://doi.org/10.1530/REP-22-0152.
44. Weng Y, Zhang Y, Wang D, et al. Exercise-induced irisin improves follicular dysfunction by inhibiting IRE1α-TXNIP/ROS-NLRP3 pathway in PCOS. J Ovarian Res 2023;16:151. https://doi.org/10.1186/s13048-023-01242-x.
45. Lai Q, Xiang W, Li Q, et al. Oxidative stress in granulosa cells contributes to poor oocyte quality and IVF-ET outcomes in women with polycystic ovary syndrome. Front Med 2018;12:518-24. https://doi.org/10.1007/s11684-017-0575-y.
46. Jing Q, Hu X, Ma Y, et al. Marine-derived natural lead compound disulfide-linked dimer psammaplin A: biological activity and structural modification. Mar Drugs 2019;17:384. doi: 10.3390/md17070384.
47. Mohammadi M. Oxidative stress and polycystic ovary syndrome: a brief review. Int J Prev Med 2019;10:86. https://doi.org/10.4103/ijpvm.IJPVM_576_17.
48. Xu Y, Qiao J. Association of insulin resistance and elevated androgen levels with polycystic ovarian syndrome (PCOS): a review of literature. J Healthc Eng. 2022;2022:9240569. https://doi.org/10.1155/2022/9240569.
49. Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): long-term metabolic consequences. Metabolism 2018;86:33-43. https://doi.org/10.1016/j.metabol.2017.09.016.
50. Kara L, Cicek D, Sarikaya E, et al. Adolescent PCOS and metabolic health: an analysis of fat, muscle, and hormones. Eur J Obstet Gynecol Reprod Biol 2025;314:114648. https://doi.org/10.1016/j.ejogrb.2025.114648.